22 Jul

#NewTrialAnnouncement

PharmaSols is delighted to be working with UNITY Biotechnology, Inc. (UNITY) on their latest ophthalmologic study UBX1325-02, across multiple sites in Australia and New Zealand.

The study is a Phase 2a, Prospective, Multicentre, Randomized, Double-Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with Diabetic Macular Oedema (DME).

UNITY’s goal with UBX1325 is to transformationally improve real-world outcomes for patients with DME, nAMD, and DR.

UNITY and PharmaSols look forward to forging a strong on-going relationship. As UNITY expands its global footprint with clinical studies, they are very excited to include AU and NZ in this important effort.

Find out more https://lnkd.in/g_MXh9U

Other News

HiRO – Top CRO in APAC 2022

The world is witnessing an enormous demand for innovative medicines to manage and cure diseases. Despite the explosive record demand levels and best efforts of pharma companies during the COVID-19 pandemic, there is still uncertainty regarding the fastest approval process defined by the FDA.

Read more
ANZ Trends Upwards in Popularity for Clinical Trials

Australia and New Zealand are considered the go-to place to conduct clinical trials for an increasing number of global sponsors. That’s not surprising as the region generates high-quality clinical data while being time- and cost-effective.

Read more
ANZ – Destination to speed up your clinical trial

Before recruiting patients for a clinical trial, the study goes through a study start-up phase which includes processes like ethics and regulatory approval & site identification/onboarding. Ethics and regulatory processes are seen as a key limiting factor in the study start-up phase of a clinical trial.

Read more